Innovative, differentiated technologies advancing new modalities: Case studies in mRNA & viral vectors
Innovative, differentiated technologies advancing new modalities: Case studies in mRNA & viral vectors
The unprecedented therapeutic potential of new modalities are accompanied by multiple new manufacturing challenges. Implementing smaller, more flexible manufacturing facilities, modalities with greater shear sensitivity, and speed to clinic, demand innovation of technologies that were largely developed for monoclonal antibodies. Innovations in upstream intensification and downstream operations that specifically benefit new modalities, like mRNA and viral vectors, are described.
Feb 23
Discover More Webinars
01
02
03
04
05
01
/
05
网络研讨会
Automating the UF/DF Process with In-Line Concentration Measurement to Reduce Cycling Time and Accelerate PD
8年5月
网络研讨会
网络研讨会
Accelerate your UF/DF process using the only in-line concentration controlled TFF system
Feb 9
网络研讨会
Disruptive technologies transforming upstream process intensification for all modalities
Feb 2
11:00 EDT